In patients with low risk (T1-3, N1), dMMR colon cancer receiving adjuvant FOLFOX or CAPOX plus atezolizumab, do you recommend 3 months, 6 months duration of chemotherapy or skipping it altogeher?  

In the ATOMIC trial evaluating the addition of adjuvant atezolizumab in this setting, patients received 6 months of chemotherapy plus 12 months total atezolizumab. However, given the IDEA data, would you consider 3 months of chemotherapy to be adequate in this population? And given the data from metastatic disease, is chemotherapy needed in this setting?